Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone LAI for Prevention of Mood Episodes in Bipolar I Disorder
NCT00391222Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2006
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of risperidone in bipolar I disorder (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Time to Recurrence of a Mood Episode (Risperidone LAI Versus Placebo) up to 21 months. Started Nov 2006; status: completed.
02
Drugs
risperidone
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT00391222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00391222.